AstraZeneca and Daiichi Sankyo continue to flesh out Enhertu plans, claiming win in earlier breast cancer line

AstraZeneca and Daiichi Sankyo have big plans for their blockbuster-in-the-making Enhertu, and the pair touted another win Monday morning in the quest to conquer the breast cancer market.

Enhertu reached its primary endpoint in a study looking at HER2-positive metastatic breast cancer patients who had previously been treated with one...

Click to view original post